ArticleFrontiers in neurology2026
Discovery of a preliminary urinary metabolite panel for Parkinson's disease: a pilot study using paired patient-spouse samples and machine learning consensus.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parkinson's disease (PD) lacks reliable non-invasive diagnostic biomarkers. Urine is a promising biofluid for biomarker discovery, but the profound influence of shared environment and lifestyle represents a major confounder. Methods: To rigorously address this, we designed a pilot study using a unique matched-pair cohort: PD patients together with their healthy spouses. Untargeted LC-MS metabolomics was performed on urine samples from 15 carefully matched pairs. Differential features were identified using VIP > 1.0 and Results: A preliminary five-metabolite panel (Cyanuric acid, Benzeneacetonitrile, 3-Formylsalicylic Acid, dADP, and ent-cassa-12,15-dien-2beta-ol) was defined. Despite the inherently small sample size of this niche cohort, the panel demonstrated promising internal discriminative performance (AUC > 0.95). Discussion: We emphasize that these results are exploratory. The primary contribution of this pilot study is not a validated diagnostic tool, but the demonstration of a carefully controlled design to isolate PD-specific metabolic signatures and the proposal of specific candidate biomarkers. This work establishes a critical proof-of-concept and prioritizes targets for essential future validation in larger, independent cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.